EGFR拮抗剂在结直肠癌治疗中的应用  

EGFR inhibitors and colorectal cancer

作　　者：易福梅[1] 王俊杰[1] 

机构地区：[1]北京大学第三医院肿瘤治疗中心,北京100191

出　　处：《现代肿瘤医学》2011年第1期188-191,共4页Journal of Modern Oncology

摘　　要：EGFR活化及其信号通路在结直肠癌生物学中起着重要作用。EGFR靶向药物为结直肠癌的治疗开创了新的方向。与酪氨酸激酶抑制剂相比,单克隆抗体已被证明有很高的疗效。西妥昔单抗作为一线、二线用药及用于化疗耐药的病人都是有效的。作为一线药物时,它的加用还可以提高肝转移灶切除率。EGFR activation and subsequent signal pathways are critical in colorectal cancer biology. Its targeting with specific drugs has opened a new window in the treatment of this disease. Monoclonal antibodies have a high degree of efficiency opposed to the uselessness of tyrosine - kinase inhibitors. Cetuximab has efficiency from the first line to heavily pretreated patients. In the first line, its addition may increase response rate to chemotherapy, improve liver metastases resection rate.

关 键 词：结直肠癌 EGFR 厄洛替尼 吉非替尼 西妥昔单抗 

分 类 号：R735.34[医药卫生—肿瘤]